Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

ClinicalTrials.gov ID: NCT00043888

Public ClinicalTrials.gov record NCT00043888. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg Twice Daily or 700mg/100mg Twice Daily) When Used in Combination With a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR Twice Daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy.

Study identification

NCT ID
NCT00043888
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
60 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2001
Primary completion
Apr 30, 2003
Completion
Apr 30, 2003
Last update posted
Feb 11, 2013

2002 – 2003

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
GSK Clinical Trials Call Center Little Rock Arkansas 72205
GSK Clinical Trials Call Center Long Beach California 90813
GSK Clinical Trials Call Center Newport Beach California 92663
GSK Clinical Trials Call Center San Diego California 92101
GSK Clinical Trials Call Center Denver Colorado 80220
GSK Clinical Trials Call Center Washington D.C. District of Columbia 20036
GSK Clinical Trials Call Center Altamonte Springs Florida 32701
GSK Clinical Trials Call Center Fort Lauderdale Florida 33308
GSK Clinical Trials Call Center Fort Lauderdale Florida 33316
GSK Clinical Trials Call Center Fort Lauderdale Florida 33334
GSK Clinical Trials Call Center Atlanta Georgia 30339
GSK Clinical Trials Call Center Greenville North Carolina 27858
GSK Clinical Trials Call Center Philadelphia Pennsylvania 19107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00043888, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 11, 2013 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00043888 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →